Both CD4 and CD8 T Cells Mediate Equally Effective In Vivo Tumor Treatment When Engineered with a Highly Avid TCR Targeting Tyrosinase

Timothy L. Frankel(National Institutes of Health), Richard A. Morgan(National Institutes of Health)
The Journal of Immunology
April 28, 2010
Cited by 82


Related Papers